Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Imatinib for Sickle Cell Anemia
Recruiting3 awardsPhase 1 & 2
Cincinnati, Ohio
This trial will test the effects of imatinib on sickle red blood cells. Imatinib will be given to patients following established guidelines, and the patients' red blood cells will be examined for changes. The trial will last six months.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.